Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SPX-1009
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : The Division of Cancer Treatment and Diagnosis
Deal Size : $0.4 million
Deal Type : Funding
Details : The grant will support the continued development of novel small molecules that inhibit the enzymatic activity of Quiescin Sulfhydryl Oxidase I (“QSOX1”) based on a lead compound. QSOX1 is a tumor-derived enzyme that is important for cancer growth, in...
Product Name : SPX-1009
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 08, 2020
Lead Product(s) : SPX-1009
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : The Division of Cancer Treatment and Diagnosis
Deal Size : $0.4 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : AXIM Biotechnologies
Deal Size : Undisclosed
Deal Type : Collaboration
Details : AXIM® Biotechnologies, has signed a binding term sheet to acquire leading oncology research and development company Sapphire Biotech as a wholly-owned subsidiary.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 01, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : AXIM Biotechnologies
Deal Size : Undisclosed
Deal Type : Collaboration